DAN-RSVHot Line 2Prevention
RSVpreF Vaccine for Preventing Cardiorespiratory Hospitalisations
RSVpreF vaccine for preventing cardiorespiratory hospitalisations
TBPresenting authorTor Biering-SørensenCardiac Imaging · Copenhagen University Hospital-Gentofte
Tor Biering-Sørensen is Professor at the Department of Biomedical Sciences, University of Copenhagen, and a consultant in the Department of Cardiology at Herlev and Gentofte Hospital. He is Founding Head of the Center for Translational Cardiology and Pragmatic Randomized Trials (CTCPR) and the Cardiovascular Non-Invasive Imaging Research Laboratory (CIRL). He previously conducted research at Brigham and Women's Hospital and Harvard Medical School.
Overview
Pending RSVpreF results leave cardiorespiratory benefit in CVD unproven; leaves open broader vaccination recommendations until full data emerge.
Key result
RSVpreF vaccine for preventing cardiorespiratory hospitalisations is currently under investigation, with late-breaking trial results pending.
Discussion
Expert reaction lands here the moment DAN-RSV reports.
Expert takes
The DAN-RSV trial was a pragmatic, open-label, individually randomized trial of 131,276 adults aged ≥60 years in Denmark that showed the RSVpreF vaccine was 83.3% effective against RSV-related respiratory hospitalization and reduced all-cause cardiorespiratory hospitalizations by 9.9%. Prespecified secondary analyses published in JAMA, JACC, and European Heart Journal examined cardiovascular outcomes and found no statistically significant reduction in isolated cardiovascular endpoints. There is meaningful expert commentary on whether RSV vaccination can reduce downstream cardiovascular complications, with an accompanying JAMA editorial and reactions from investigators and outside experts.
Mats C. Højbjerg Lassen
Research Fellow, Copenhagen University Hospital-Gentofte
“Similar to what we have seen with the influenza vaccines, people with a chronic cardiovascular disease are at increased risk of hospitalizations with worsening of their preexisting disease or triggering of new coronary events with respiratory viruses such as flu, RSV, and COVID-19. Preventing these acute infections during the winter season may help keep them out of hospital.”
TB
Tor Biering-Sørensen
Cardiologist, Copenhagen University Hospital-Gentofte
“The findings suggest potential downstream cardiorespiratory benefits of RSV immunization. The results support broader consideration of RSV vaccination in older adults, including among those with CVD, as part of a strategy to reduce severe cardiorespiratory complications.”
HY
Helen Y. Chu
Infectious disease physician, University of Washington
“RSV has traditionally been underrecognized by clinicians as a cause of cardiopulmonary hospitalizations.”
Key Points
- The clinical trial evaluates whether the RSVpreF vaccine effectively reduces subsequent cardiorespiratory hospitalisations in vulnerable patient populations.
- Presented as a late-breaking clinical trial at ESC Congress 2026, the investigation focuses on respiratory syncytial virus prevention across healthcare centres.
- With full outcome results pending release, the trial highlights the potential of targeted vaccination to decrease acute cardiorespiratory hospitalisations globally.
Main Result
Absolute Event Rate: 0% vs 0%